Taysha Gene Therapies
Kamran Alam is a finance executive with experience with follow-on financings and M&A, served as VP Finance at AveXis where he played a key role in the acquisition of AveXis by Novartis, most recently served as SVP Finance and Principal Financial Officer at Rocket Pharma.
This person is not in any offices
Taysha Gene Therapies
Taysha Gene Therapies is on a mission to eradicate severe and life-threatening monogenic CNS disease. With a singular focus on developing curative medicines, they hope to rapidly translate their treatments from bench to bedside.